Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
CURRENT ASSETS
Cash and cash equivalents	$ 6,463	$ 16,420
Total current assets	13,007	23,274
Restricted cash	1,426	3,528
Property and equipment, net	11,433	12,886
Operating lease right-of-use assets	7,239	11,516
Other non-current assets	0	19
TOTAL ASSETS	33,105	51,223
CURRENT LIABILITIES
Accounts payable	2,248	2,943
Accrued expenses and other current liabilities	4,082	5,354
Convertible notes - related party	3,993	0
Operating lease liabilities, current	3,492	5,330
GeneFab sublease deferred income - related party	1,939	304
Deferred revenue - related party	11	43
Total current liabilities	15,765	13,974
Operating lease liabilities, non-current	12,741	23,561
Other non-current liabilities	8,000	8,099
TOTAL LIABILITIES	36,506	45,634
Commitments and contingencies (Note 14)
STOCKHOLDERS’ EQUITY (DEFICIT)
Common stock, $0.0001 par value; 500,000,000 shares authorized as of both June 30, 2026 and December 31, 2025; 31,144,754 and 30,879,355 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	3	3
Additional paid-in capital	372,139	364,158
Accumulated deficit	(375,543)	(358,572)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	(3,401)	5,589
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	33,105	51,223
Nonrelated Party
CURRENT ASSETS
Accounts receivable	0	323
Prepaid expenses and other current assets	1,055	1,655
Related Party
CURRENT ASSETS
Accounts receivable	557	1,272
Prepaid expenses and other current assets	$ 4,932	$ 3,604